This company listing is no longer active
La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
MorphoSys Performance dei guadagni passati
Il passato criteri di controllo 0/6
MorphoSys's earnings have been declining at an average annual rate of -27.6%, while the Biotechs industry saw earnings growing at 16.1% annually. Revenues have been growing at an average rate of 11% per year.
Informazioni chiave
-27.6%
Tasso di crescita degli utili
-26.8%
Tasso di crescita dell'EPS
Biotechs Crescita del settore | 17.0% |
Tasso di crescita dei ricavi | 11.0% |
Rendimento del capitale proprio | n/a |
Margine netto | -194.0% |
Prossimo aggiornamento sui guadagni | 07 Aug 2024 |
Aggiornamenti sulle prestazioni recenti
Recent updates
MorphoSys: Hold Rating Until The Novartis Deal Closes
May 01Novartis And MorphoSys Are A Perfect Match
Feb 06MorphoSys: Positive Pelabresib Data Finally Unlocking Upside
Jan 18MorphoSys updates Q2 & FY22 guidance below prior provided levels
Jul 26MorphoSys May Not Recover From Adventurous Constellation Buyout
May 04Sierra Oncology's Strong Data In Myelofibrosis Challenges MorphoSys And Incyte
Jan 28Incyte and MorphoSys presents new three-year data for blood cancer therapy
Jun 04MorphoSys reports Q1 results
May 05MorphoSys AG appoints Sangamo 's Sung Lee as new CFO
Jan 06MorphoSys AG (MOR) Investor Presentation - Slideshow
Dec 08MorphoSys AG 2020 Q3 - Results - Earnings Call Presentation
Nov 22MorphoSys reports Q3 results
Nov 11Ripartizione dei ricavi e delle spese
Come MorphoSys guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
---|---|---|---|---|
31 Mar 24 | 241 | -469 | 337 | 294 |
31 Dec 23 | 238 | -190 | 147 | 274 |
30 Sep 23 | 223 | 104 | 128 | 271 |
30 Jun 23 | 255 | 100 | 133 | 286 |
31 Mar 23 | 261 | -61 | 130 | 290 |
31 Dec 22 | 278 | -151 | 153 | 290 |
30 Sep 22 | 250 | -861 | 143 | 289 |
30 Jun 22 | 195 | -851 | 156 | 276 |
31 Mar 22 | 174 | -596 | 178 | 255 |
31 Dec 21 | 180 | -514 | 180 | 224 |
30 Sep 21 | 163 | -150 | 196 | 191 |
30 Jun 21 | 143 | -103 | 191 | 160 |
31 Mar 21 | 124 | -177 | 175 | 151 |
31 Dec 20 | 328 | 98 | 159 | 125 |
30 Sep 20 | 303 | 64 | 140 | 104 |
30 Jun 20 | 293 | 105 | 107 | 96 |
31 Mar 20 | 309 | 153 | 75 | 90 |
31 Dec 19 | 72 | -103 | 59 | 107 |
30 Sep 19 | 71 | -96 | 42 | 101 |
30 Jun 19 | 114 | -42 | 35 | 94 |
31 Mar 19 | 87 | -59 | 31 | 95 |
31 Dec 18 | 76 | -56 | 28 | 87 |
30 Sep 18 | 94 | -27 | 25 | 85 |
30 Jun 18 | 54 | -82 | 23 | 101 |
31 Mar 18 | 58 | -74 | 21 | 98 |
31 Dec 17 | 67 | -70 | 21 | 103 |
30 Sep 17 | 52 | -84 | 17 | 106 |
30 Jun 17 | 49 | -73 | 16 | 94 |
31 Mar 17 | 49 | -68 | 15 | 90 |
31 Dec 16 | 50 | -60 | 16 | 84 |
30 Sep 16 | 49 | -45 | 15 | 81 |
30 Jun 16 | 48 | -40 | 15 | 78 |
31 Mar 16 | 48 | -33 | 15 | 79 |
31 Dec 15 | 106 | 15 | 15 | 75 |
30 Sep 15 | 111 | 27 | 14 | 64 |
30 Jun 15 | 116 | 33 | 14 | 62 |
31 Mar 15 | 119 | 37 | 14 | 55 |
31 Dec 14 | 64 | -3 | 14 | 52 |
30 Sep 14 | 61 | -6 | 16 | 53 |
30 Jun 14 | 60 | -5 | 17 | 48 |
31 Mar 14 | 77 | 7 | 18 | 48 |
31 Dec 13 | 78 | 7 | 18 | 48 |
30 Sep 13 | 80 | 14 | 17 | 44 |
Guadagni di qualità: MOR is currently unprofitable.
Margine di profitto in crescita: MOR is currently unprofitable.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: MOR is unprofitable, and losses have increased over the past 5 years at a rate of 27.6% per year.
Accelerare la crescita: Unable to compare MOR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Guadagni vs Settore: MOR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-34.5%).
Rendimento del capitale proprio
ROE elevato: MOR's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.